HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study

Trastuzumab has been approved for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction cancers (GC and GJC) in combination with chemotherapy. The aim of this HER2 early/advanced gastric epidemiology (HER-EAGLE) study was to evaluate the frequency of...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Dan, Lu, Ning, Fan, Qinhe, Sheng, Weiqi, Bu, Hong, Jin, Xiaolong, Li, Guimei, Liu, Yanhui, Li, Xianghong, Sun, Wenyong, Zhang, Huizhong, Li, Xiaobing, Zhou, Zongguang, Yan, Min, Wang, Xuan, Sha, Weihong, Ji, Jiafu, Cheng, Xiangdong, Zhou, Zhiwei, Xu, Jianming, Du, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828190/
https://www.ncbi.nlm.nih.gov/pubmed/24244671
http://dx.doi.org/10.1371/journal.pone.0080290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828190/
https://www.ncbi.nlm.nih.gov/pubmed/24244671
http://dx.doi.org/10.1371/journal.pone.0080290

Ejemplares similares